Market Place
Sourcing Support
Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis
26 Jun 2024 //
PR NEWSWIRE
Synaptogenix & Cleveland to Submit IND Application for Trial of Bryostatin-1
19 Jul 2023 //
PR NEWSWIRE
Extended Therapeutic Potential of Synaptogenix`s Bryostatin for AD
05 Apr 2022 //
PRNEWSWIRE
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1
23 Feb 2022 //
PRESS RELEASE
BryoLogyx Announces Completion of World’s First GMP Synthesis of Bryostatin-1
12 Oct 2020 //
BUSINESSWIRE
Aphios Granted US Patent for Oral Administration of Bryostatin-1 Nanoparticles
05 Dec 2019 //
BUSINESSWIRE
Neurotrope shares crash after Alzheimer`s drug fails in trial
10 Sep 2019 //
REUTERS
Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1
13 Mar 2019 //
PR NEWSWRE
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with NCI
04 Feb 2019 //
PR NEWSWIRE
Neurotrope & NCI Enter Development Agreement
04 Jan 2019 //
CONTRACT PHARMA
Neurotrope Enters Collaboration with Nemours forFragile X Syndrome
06 Sep 2018 //
PR NEWSWIRE
Neurotrope announces +ve top-line results from phase 2 study of Bryostatin-1
02 May 2017 //
PHARMABIZ
Neurotrope completes patient dosing in phase 2 study of bryostatin
24 Nov 2016 //
PHARMABIZ
Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome
09 Apr 2015 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.